![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves First Non-Injected Glucagon Treatment for Severe Hypoglycemia
FDA Approves First Non-Injected Glucagon Treatment for Severe Hypoglycemia
July 30, 2019
The FDA has approved Eli Lilly’s Baqsimi nasal powder 3 mg, making it the first needleless glucagon therapy OK’d by the agency for the emergency treatment of severe hypoglycemia.
The drug is the first and only nasally-administrated glucagon treatment indicated for diabetic patients aged four and above experiencing severe hypoglycemia, a dangerously low level of blood sugar.
The condition is very serious for type 1 and type 2 diabetes patients and can lead to seizures, comas and even death if not treated properly.
Upcoming Events
-
21Oct